NEU

Healthcare & BiotechCOILED

$16.700

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted

NIBInvestment banks+$40.7M

MMMarket makers+$4.8M

WAWealth & advisers+$2.3M

RetailRetail · context+$1.4M

ResResource specialists+$166k

5d return

-1.5%

20d return

+0.6%

60d return

+33.9%

RSI 14

54.3

vs 52w high

-24.0%

vs 52w low

+48.0%

SMA 20

Below

SMA 50

Above

Price · Volume · Broker flow

Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.

Loading chart…

Closest correlates

Pearson r on log returns, window: 42d

Announcements — last 30 days

2026-07-24Neuren highlights participation in PMSF Family Conference
2026-06-29PSSTARDAYBU recommended for approval in the European Union
CHMP recommendation positions DAYBU as Europe's first approved Rett syndrome treatment, unlocking $35M upfront plus substantial milestone and royalty streams from Acadia's commercialization. Pending EC approval in coming months, this de-risks international revenue and validates NEU's IGF-1 therapeutic platform across multiple rare pediatric indications.